Dr. Robert Coleman, CEO of Codagenix, discusses their innovative approach to virus engineering, which includes developing a nasally-delivered COVID-19 vaccine that targets multiple virus proteins for broader protection. Codagenix's "rational virus design" method creates genetically stable vaccines and therapeutics, reducing the risk of harmful mutations. Their work also extends to vaccines for other diseases and viral-based cancer treatments, with the potential to significantly advance global health.